Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Steven M, Keller"'
Autor:
Mary O’Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters
Publikováno v:
The Lancet Oncology. 23:1274-1286
Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC.In this randomised, triple-blind, phase 3 trial (PEARLS/KEYNOTE-091), patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::546d56085895273ebf924ed87a7e4b0b
https://doi.org/10.1016/s1470-2045(22)00518-6
https://doi.org/10.1016/s1470-2045(22)00518-6
Autor:
Hayley M. McDaid, Susan Band Horwitz, Roman Pérez-Soler, Steven M. Keller, Lluis Lopez-Barcons, Han-Guang Yan, Chia-Ping Huang Yang, Marie-Emmanuelle Legrier
Supplementary Figure 2 from Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d3a3928cb8aeefabd4d41decee65650
https://doi.org/10.1158/0008-5472.22370444
https://doi.org/10.1158/0008-5472.22370444
Autor:
Hayley M. McDaid, Susan Band Horwitz, Roman Pérez-Soler, Steven M. Keller, Lluis Lopez-Barcons, Han-Guang Yan, Chia-Ping Huang Yang, Marie-Emmanuelle Legrier
Supplementary Figure 1 from Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b3539fe814899d847117833e66aa6f3
https://doi.org/10.1158/0008-5472.22370447.v1
https://doi.org/10.1158/0008-5472.22370447.v1
Autor:
Hayley M. McDaid, Susan Band Horwitz, Roman Pérez-Soler, Steven M. Keller, Lluis Lopez-Barcons, Han-Guang Yan, Chia-Ping Huang Yang, Marie-Emmanuelle Legrier
Lung cancer is a genetically heterogeneous disease characterized by the acquisition of somatic mutations in numerous protein kinases, including components of the rat sarcoma viral oncogene homolog (RAS) and AKT signaling cascades. These pathways inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb3d16cadc35a9bb630b4209b8c2da4d
https://doi.org/10.1158/0008-5472.c.6496403
https://doi.org/10.1158/0008-5472.c.6496403
Autor:
Hayley M. McDaid, Susan Band Horwitz, Roman Pérez-Soler, Steven M. Keller, Lluis Lopez-Barcons, Han-Guang Yan, Chia-Ping Huang Yang, Marie-Emmanuelle Legrier
Supplementary Figure 3 from Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065054aa9191469460d936e47d774772
https://doi.org/10.1158/0008-5472.22370441.v1
https://doi.org/10.1158/0008-5472.22370441.v1
Autor:
Stephen L. Graziano, Joan H. Schiller, Charles A. Butts, Conor E. Steuer, Steven M. Keller, Suresh S. Ramalingam, Opeyemi Jegede, Alex A. Adjei, William J. Tester, David R. Gandara, Heather A. Wakelee, Suzanne E. Dahlberg
Publikováno v:
J Thorac Oncol
Introduction Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB–IIIA NS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee455abf186b3375e0739b398ec934bf
https://doi.org/10.1016/j.jtho.2020.12.017
https://doi.org/10.1016/j.jtho.2020.12.017
Autor:
Yuting Kuang, Christine M. Pierce, Hsiu-Ching Chang, Alexandra Z. Sosinsky, Anne C. Deitz, Steven M. Keller, Ayman Samkari, Jennifer Uyei
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 174
High-grade pneumonitis is a severe and potentially life-threatening adverse event associated with concurrent chemoradiation (cCRT) in patients with non-small cell lung cancer (NSCLC). The aim of this study was to summarize and quantify the incidence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7375ee83879e70c3bf15cab8e2d9108b
https://pubmed.ncbi.nlm.nih.gov/35717343
https://pubmed.ncbi.nlm.nih.gov/35717343
Autor:
Dariusz M. Kowalski, Keunchil Park, Vishal Boolell, Salma K. Jabbour, Steven M. Keller, Valeriy Breder, Amy Sanford, Nikolaj Frost, Baerin Houghton, A. Samkari, Martin Reck, Ki Hyeong Lee, Noemi Reguart, Hong Liu, Alex Martinez-Marti, Takefumi Komiya, Theodore Pollock, Jean Baptiste Paoli, Sufia Safina, Evgeny Levchenko
Publikováno v:
JAMA Oncol
IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7609733e2099c09e1daaebba833b59f
https://europepmc.org/articles/PMC8446818/
https://europepmc.org/articles/PMC8446818/
Autor:
Thomas J. Belbin, John Gaspar, Missak Haigentz, Roman Perez-Soler, Steven M. Keller, Michael B. Prystowsky, Geoffrey Childs, Nicholas D. Socci
Publikováno v:
BioTechniques, Vol 36, Iss 2, Pp 310-314 (2004)
The use of universal RNA reference sets is an increasingly common approach to molecular classification studies with cDNA microarrays. Here we evaluated the reliability of indirect measurements of fluorescence ratios with a common RNA reference as a m
Externí odkaz:
https://doaj.org/article/3cd40639812d4396b20aa3e043a6a95b
Autor:
Vassiliki A. Papadimitrakopoulou, Ryan D. Gentzler, Lecia V. Sequist, Renato G. Martins, James P. Stevenson, Shirish M. Gadgeel, Matthew A. Gubens, Mark M. Awad, Leena Gandhi, Corey J. Langer, Amita Patnaik, Joseph Fiore, Hossein Borghaei, Steven Francis Powell, Amit Panwalkar, Shadia I. Jalal, James Chih-Hsin Yang, Sanatan Saraf, Steven M. Keller
Publikováno v:
Journal of Thoracic Oncology. 14:124-129
Introduction Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the primary analysis (median follow-up tim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eba60487607901356e9cd5251e5ef87
https://doi.org/10.1016/j.jtho.2018.08.004
https://doi.org/10.1016/j.jtho.2018.08.004